Roche announces the development of investigational molecule bitopertin in β-thalassemia and informs the patient community that the company has recently started a clinical study testing the efficacy of this molecule in people with β-thalassemia.
About the study
This study, called βitoThal or BP39642, is evaluating the use of bitopertin in people with non-transfusion dependent (NTD) β-thalassemia. The βitoThal (BP39642) study aims to explore the safety, tolerability and efficacy of bitopertin, a molecule given by mouth. It is an open-label study of 22 weeks duration in up to 24 subjects where all participants will be given bitopertin. Countries involved in the study are Italy, Lebanon and Thailand.
Read more here